| Document |
Document Title |
|
WO/2024/047674A1 |
The present invention provides a novel manganese catalyst (Formula I) and their process of preparation thereof. The present invention also provides process of hydrogenation wherein the novel manganese catalyst used for hydrogenation of v...
|
|
WO/2024/016976A1 |
The present invention relates to a FAP-α specific tumor diagnostic imaging agent, in particular, the present invention relates to a compound of formula (I), a FAP-α specific tumor imaging agent formed by coordination of the compound of...
|
|
WO/2023/246564A1 |
The present invention relates to a marked fatty acid derivative, a precursor compound thereof, and use thereof in a contrast agent. The derivative is represented by formula I: wherein M is 99mTc or Re; R, R1, R2, R3, R4 and R5, and A1-A1...
|
|
WO/2023/226281A1 |
The present invention provides a manganese (II) complex based on a tricyclohexylphosphine structure, a synthesis method therefor, and an application thereof. Organic cations are obtained first by means of ionization, and the organic cati...
|
|
WO/2023/144482A1 |
The present invention relates to a process for hydrogenating esters in the presence of a manganese catalyst, and to a manganese catalyst that can be used for carrying out said process.
|
|
WO/2023/139322A1 |
The present invention relates to hydrosilylation reactions between a monosubstituted alkene compound and a compound comprising at least one hydrogen atom bonded to a silicon atom. More specifically, the invention relates to a process for...
|
|
WO/2023/122564A2 |
A tissue-specific manganese based magnetic resonance imaging (MRI) agent includes the formula: wherein T includes at least one cell specific or tissue specific targeting moiety; C includes at least one pyclen based chelating agent comple...
|
|
WO/2023/030509A1 |
A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSM...
|
|
WO/2023/029683A1 |
Disclosed are a scintillating material and a preparation method therefor and an application thereof. The chemical formula of the scintillating material is C42H42X2MnO2P2, wherein X is selected from one of Cl and Br. The scintillating mat...
|
|
WO/2023/009500A1 |
A method of enhancing wound healing after a radiation exposure in a mammalian subject is provided. The mammalian subject is selected from among a population of mammalian subjects that has been or will be exposed to radiation, and the mam...
|
|
WO/2023/001004A1 |
The present invention relates to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular to a mannose derivative and an application thereof. The mannose derivative is an isonitrile-containin...
|
|
WO/2023/281046A1 |
The present invention provides novel bispidone ligands and transition metal complexes thereof, especially iron and manganese complexes thereof. Furthermore, the present invention also relates to the use of said bispidone ligands and comp...
|
|
WO/2022/268525A1 |
A process for hydrogenating an ester of the general formula (III) with molecular hydrogen to the alcohols (a) and (b) at a temperature of 50 to 200°C and a pressure of 0.1 to 20 MPa abs in the presence of a manganese(I) complex, the man...
|
|
WO/2022/257895A1 |
The present invention relates to an intermediate for fulvestrant and a preparation method therefor. Specifically, the present invention relates to a compound of formula V and a preparation method therefor, wherein R1 is hydrogen or hydro...
|
|
WO/2022/256897A1 |
The present disclosure is directed to chelated nutrients having a structure [M(Ligand 1)(Ligand 2)]2Y, wherein: M is a metal selected from the group consisting of Cu, Mn, Zn, Co, Ni, Mg, Ca and Fe; Ligand 1 is glutamic acid; Ligand 2 is ...
|
|
WO/2022/253785A2 |
The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to...
|
|
WO/2022/231410A1 |
The invention relates to new radiopharmaceuticals that inhibit fibroblast activation protein (iFAP), which are based on the molecule ((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl)pyrrolidin-2-yl)bo
ronic acid (HYNIC-iFAP), wherein the nitrog...
|
|
WO/2022/204701A1 |
Methods of growing large, free-standing single crystals of (FAxCs1-x)PbBr3 perovskites, where 0 ≤ x < 1, in solution using tertiary or ternary alkyl ammonium salts, weak organic acids, or a combination thereof are provided. By includin...
|
|
WO/2022/158442A1 |
The present invention provides, as a radioactive halogen-labeled precursor compound that is highly stable and reactive, a compound represented by general formula (II) [in the formula, R1 and R2 each independently represent an alkyl group...
|
|
WO/2022/130796A1 |
Provided are: a photoacid generator that effectively generates acid even when there is a high concentration of a substance such as a colorant that attenuates or shields irradiated light, and even when the film thickness is great and a li...
|
|
WO/2022/109188A1 |
Provided herein are radiolabeled liposomes and methods of use thereof. In one aspect, is a method of treating a disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a radiolabel...
|
|
WO/2022/077923A1 |
The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, in particular to a benzene ring-containing glucose derivative and an application thereof. The benzene ring-containing gl...
|
|
WO/2022/040045A1 |
Provided herein are SOD mimetic compounds comprising substituted porphyrins. Also provided are methods of treating coronavirus infections and symptoms associated thereto with substituted porphyrin SOD mimetic compounds. The compounds des...
|
|
WO/2022/034313A1 |
The present invention relates to compounds of Formula I: wherein R1, L1, A, Xa, L2, B and Xb are each as defined herein. The present invention also relates to compounds of Formula II and III defined herein, formed by self-assembly of the...
|
|
WO/2022/034987A1 |
Disclosed is a method for manufacturing a perovskite thin film solar cell, wherein a light absorption layer, with two types of structures, for a perovskite solar cell is manufactured using chemical vapor deposition (CVD). The manufacturi...
|
|
WO/2022/025333A1 |
The present invention relates to a vapor deposition compound capable of being deposited as a thin film through vapor deposition and, in particular, to: an organometal-containing compound which can be applied to atomic layer deposition (A...
|
|
WO/2022/010327A1 |
A perovskite composite according to one example of the present disclosure comprises a perovskite and methylammonium chloride (MACl, CH3NH3Cl), wherein the perovskite contains an organic cation (A), a metal cation (M), and a halogen anion...
|
|
WO/2021/245148A1 |
Complex containing betaine, transition metal and sulfate in a ratio of 1:1:1, the transition metal being coordinated with two oxygen atoms from the betaine.
|
|
WO/2021/221259A1 |
An organic-inorganic perovskite compound according to the present invention contains: monovalent amidinium cations, monovalent alkylammonium cations and divalent alkylenediammonium cations as organic cations; divalent metal ions and alka...
|
|
WO/2021/177359A1 |
This ammonia decomposition method is a method for obtaining nitrogen, protons, and electrons by oxidative decomposition of ammonia in the presence of a base, using as a catalyst a salen-manganese complex in which manganese is used as a b...
|
|
WO/2021/175338A1 |
A prostate specific membrane antigen (PSMA) combining compound, a radioactive isotope complex thereof, and the use thereof in nuclear medicine as a tracer and an imaging agent for different disease states of prostate cancer.
|
|
WO/2021/172842A1 |
Disclosed are a method for preparing a perovskite compound and a perovskite photoelectric device comprising same. A method for preparing a perovskite compound according to an embodiment of the present invention comprises the steps of: pr...
|
|
WO/2021/163397A1 |
The present disclosure encompasses solid state forms of Avasopasem manganese, in embodiments crystalline polymorphs of Avasopasem manganese, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/133085A2 |
The present invention relates to a preparation method for an organic halide for preparation of perovskite, perovskite prepared thereby, and a solar cell. According to the present invention, an organic halide for perovskite can be prepare...
|
|
WO/2021/043926A1 |
The invention relates to isomers of chelate compounds and their use as contrast agents in magnetic resonance imaging (MRI) procedures.
|
|
WO/2020/255913A1 |
The present invention relates to a starting material for chemical vapor deposition for producing a manganese thin film or a manganese compound thin film by a chemical vapor deposition method, said starting material for chemical vapor dep...
|
|
WO/2020/243287A1 |
A method of making a perovskite layer includes providing a flexible substrate; providing a perovskite solution comprising an initial amount of solvent and perovskite precursor materials and a total solids concentration between 30 percent...
|
|
WO/2020/221705A1 |
The present invention relates to a novel process for preparing a compound of formula (III) and rhenium chelated MAG3 oligonucleotides.
|
|
WO/2020/218527A1 |
An ionic solid having void spaces in which a substance is to be incorporated.
|
|
WO/2020/215014A1 |
The present disclosure is directed to perovskite-based solar cell device structures and compositions comprising one or more near infrared sensitive semiconducting materials. The near infrared sensitive semiconducting materials can extend...
|
|
WO/2020/179420A1 |
Provided is a novel compound capable of efficiently introducing CO into cells. The novel compound is represented by formula (A). In the formula, R represents hydrogen or an alkyl group which has 1-8 carbon atoms and optionally has a subs...
|
|
WO/2020/144476A1 |
The invention provides a method comprising hydrogenating a ketone in the presence of (i) a base, (ii) hydrogen gas and (iii) a catalyst comprising a charged or neutral complex of formula (I): (I) wherein: Mn is a manganese atom or a mang...
|
|
WO/2020/094789A1 |
Inventors have shown that sub-lethal concentrations of H2O2-exposure initiated a DNA damage response illustrated by increased ϒH2AX and 53BP1 expression and foci formation mainly in sensory hair cells, together with increased levels of ...
|
|
WO/2020/088187A1 |
Disclosed are a novel organometallic complex, an organic electronic device thereof and the uses thereof, particularly in organic phosphorus light emitting diodes. Also disclosed are an electronic device thereof containing the organometal...
|
|
WO/2020/074142A1 |
Catechol metal complex compounds of formula (I), wherein R1 and R2 independently of one another represent a hydrocarbon radical having 1 to 20 carbon atoms which is optionally substituted with at least one radical selected from hydroxyl,...
|
|
WO/2020/034164A1 |
Through the use of a rhodamine appended chelate, a versatile strategy has been demonstrated to generate mitochondria-targeting photosensitizers via the incorporation of variety of luminescent transition metal systems. The generation of t...
|
|
WO/2020/037166A1 |
A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium ...
|
|
WO/2019/218275A1 |
Disclosed are a polyacid hybrid compound guided by metal ions and functionalized by a carboxylate ligand, a preparation method therefor and the use thereof in the catalytic degradation of chemical warfare agent simulants. In the method, ...
|
|
WO/2019/177449A1 |
The invention relates to a new lutetium-177 therapeutic radiopharmaceutical as an inhibitor of prostate-specific membrane antigen (iPSMA), wherein 1,4,7,10-tetraazacyclododecane-N,N´,N´´,N´´´´-tetraac
etic acid (DOTA) bonded to th...
|
|
WO/2019/123409A1 |
Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ...
|
